December 17, 2015 — ArtVentive Medical Group conducted its first animal study of its next generation of the ArtVentive Endoluminal Occlusion System (EOS Gen II). The EOS is designed for use in the peripheral vasculature and offers immediate and permanent vessel occlusion in arterial and venous settings.
According to ArtVentive President and CTO Leon Rudakov, Ph.D., the second-generation EOS device offers several advantages, including profile reductions, reversibility, enhanced control over deployment and the opportunity to advance into new indications.
The ArtVentive EOS is a catheter-based, self-expandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The device is designed to serve as a safe and reliable alternative to major surgery in certain cases.
For more information: www.artventivemedical.com